ASCO 2019 Breast Cancer Keywords

#ASCO2019, abemaciclib, ado-trastuzumab emtansine, Afinitor, AI, AKT, AKT1, Aromasin, AstraZeneca, atezolizumab, AZ, AZD5363, Biocon, BRCA, capecitabine, capivasertib, carboplatin, CDK4/6, chemotherapy, cisplatin, CNS metastases, cobimetinib, Cotellic, cyclophosphamide, docetaxel, Eli Lilly, Ellence, endocrine therapy, epirubicin, ER-positive, eribulin mesylate, ESR1, everolimus, Exelixis, exemestane, Faslodex, Femara, fulvestrant, gemcitabine, Gemzar, Genentech, GnRH, goserilin, Halaven, HER2-negative, HER2-positive, Herceptin, hormonal therapy, HR-positive, Ibrance, Jiangsu HengRui Medicine, Kadcyla doxorubicin, Keytruda, Kisqali, LABC, lapatinib, letrozole, Lynparza, MacroGenics, margetuximab, MEK, Merck, MSD, mTor, Mylan, nab-paclitaxel pembrolizumab, neoadjuvant, neratinib, Nerlynx, Novartis, NSAI, OfS, Ogivri, olaparib, paclitaxel, palbociclib, PARP, PARPi, pCR, PD-L1, Perjeta, pertuzumab, Pfizer, Pharmorubicin, postmenopausal, PR-positive, premenopausal, Puma, pyrotinib, RAD001, RB1, ribociclib, Sanofi, T-DM1, TAC, taxane, Taxotere, Tecentriq, TNBC, trastuzumab, trastuzumab-dkst, triptorelin, Tykerb, Verzenio, vinolrebine, Xeloda, Zoladex